Some great #SpA posters on #WorkParticipation #ACR21 Abs#0358 •~700 pts •379 (64.2%) took sick leave in last 12m •#Absenteeism in 23.7% & #presenteeism in 84.1% •Huge impact on work participation in SpA despite incr no. of therapeutic agents @RheumNow https://t.co/pwz4s8D1FU https://t.co/wpbjeXNpgm

#ACR21 1st/2 abstracts by @ElenaNikiUK on #work & #sickleave in #SpA Abs#0380 •~700pts •Old age & high disease activity👉🏼 ⬆️risk of sick leave •Must address #socioeconomic factors w/ disease activity to improve work outcomes in #SpA @RheumNow #ACRBest https://t.co/uixuGGEFJG https://t.co/WZoqWLaY1Q

#ACR21 Abs#0101 on recombinant #zoster vaccine (RZV) in #IMIDs: •High proportion of ≥50yos w/ IMIDs received RZV but 15–25% did not get 2nd dose within 6m •#Vaccination higher in ≥65yos than 50–64yos •Need better vaccine policy to encourage uptake in pts w/ IMIDs @RheumNow https://t.co/i5JDJClTyQ

Freq & severity of adverse events after #SARSCoV2 #vaccine in patients with autoimmune disease vs controls Abs#0104 #ACR21 •No incr. risk of AEs in autoimmune disease vs controls •Minimal impact of vaccines on disease activity @RheumNow https://t.co/jGXP5UL4LP https://t.co/980NLWQYeX

@RheumNow Janet Zeide @Wharton - if the purpose = persuade: e.g. persuading an audience, persuading pts to change - ethos/logos/pathos - remove barriers to action (cost of not changing, incremental change) - state & refute counter-arguments - know & engage your audience #ACR21 @RheumNow https://t.co/JU2WeNYDvz

So how do we treat this long COVID thing? Some sensible hints here, but sadly I can't really say that we've got this under control. I feel helpless with the long COVID patients I've cared for. #ACR21 8M406 @RheumNow @galbamd @CCalabreseDO @philipcrobinson https://t.co/Vaw0QlUx50

Given the choice, you want me to risk long COVID? No thanks. #GetVaccinated #ACR21 8M406 @RheumNow @galbamd @CCalabreseDO @philipcrobinson https://t.co/TCao34vWK8